Creating a new treatment for bronchopulmonary dysplasia in preterm infants
Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia
This study is testing a new treatment for bronchopulmonary dysplasia (BPD) in preterm babies, using a special compound that helps reduce lung stress and inflammation, with the hope of making their lungs healthier and improving their overall well-being.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Reneurogen, LLC NIH-funded |
| Lab location | 1 site (Elm Grove, United States) |
| Project ID | NIH-10888168 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for bronchopulmonary dysplasia (BPD), a serious lung condition affecting preterm infants. The approach involves using a bioengineered tripeptide called N-acetyl-lysyltyrosylcysteine amide (KYC) that targets oxidative stress and inflammation in the lungs. By conducting preclinical studies on safety and effectiveness, the research aims to gather essential data for FDA approval. If successful, this treatment could significantly improve lung health and overall outcomes for affected infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants at risk of developing bronchopulmonary dysplasia.
Not a fit: Patients who are not preterm or do not have bronchopulmonary dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that improves lung growth and survival rates in preterm infants with bronchopulmonary dysplasia.
How similar studies have performed: Preliminary studies have shown promise with similar approaches, indicating potential for success in this novel treatment.
Where this research is happening
Elm Grove, United States
- Reneurogen, LLC — Elm Grove, United States (Active)
Researchers
- Principal investigator: Naylor, Stephen — Reneurogen, LLC
- Study coordinator: Naylor, Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.